Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The ELiSA Study: Lixivaptan in ADPKD
NCT03487913Phase 2Completed
- Sponsor
- Palladio Biosciences
- Start
- Sep 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lixivaptan in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Palladio Biosciences. Started Sep 2018; status: completed.
02
Drugs
lixivaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT03487913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03487913.